CLAIMS

1. A liquid pharmaceutical composition adapted for oral administration comprising
   a) tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient at a concentration of at least 0.04 mg/ml, preferably at least 0.20 mg/ml, more preferably at least 0.25 mg/ml;
   b) a buffering agent:
   c) a preservative; and
   d) water;
   wherein the pH of the composition is from about 2.0 to about 5.0, preferably from about 2.1 to about 4.0, more preferably from about 2.5 to about 3.5, still more preferably from about 2.9 to about 3.1.

2. The composition according to claim 1, wherein the active ingredient is tasipimidine sulfate.

3. The composition according to claim 1 or 2, wherein the composition is a liquid pharmaceutical composition adapted for oral administration to a human.

4. The composition according to any one of claims 1 to 3, which comprises about 0.004 – 0.3 %, preferably about 0.01 – 0.1 %, more preferably about 0.02 – 0.05 %, per weight of the composition, of tasipimidine, or a pharmaceutically acceptable salt thereof.

5. The composition according to any one of claims 1 to 4, wherein the buffering agent is citric acid/sodium citrate buffer.

6. The composition according to any one of claims 1 to 5, wherein the preservative is a benzoic acid salt.

7. The composition according to claim 6, wherein the preservative is sodium benzoate.

8. The composition according to any one of claims 1 to 7, which comprises
   a) tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient at a concentration of at least 0.04 mg/ml, preferably at least 0.2 mg/ml, more preferably at least 0.25 mg/ml;
   b) citric acid/sodium citrate buffer;

c) sodium benzoate; and

d) water;

wherein the pH of the composition is from about 2.0 to about 5.0, preferably from about 2.1 to about 4.0, more preferably from about 2.5 to about 3.5, still more preferably from about 2.9 to about 3.1.

9. The composition according to any one of claims 1 to 8 which comprises

a) 0.004 – 0.3 %, per weight of the composition, of tasipimidine, or a pharmaceutically acceptable salt thereof;

b) 0.05 – 4.5 %, per weight of the composition, of a buffering agent;

c) 0.01 – 1 %, per weight of the composition, of a preservative; and

d) 96 – 98 %, per weight of the composition, of purified water;

wherein the pH of the composition is from about 2.0 to about 5.0, preferably from about 2.1 to about 4.0, more preferably from about 2.5 to about 3.5, still more preferably from about 2.9 to about 3.1.

10. The composition according to claim 9 which comprises

a) 0.01 – 0.1 %, per weight of the composition, of tasipimidine or a pharmaceutically acceptable salt thereof;

b) 2.0 – 2.7 %, per weight of the composition, of citric acid/citrate buffer;

c) 0.02 – 0.5 %, per weight of the composition, of a benzoic acid salt; and

d) 97 – 97.9 %, per weight of the composition, of purified water;

wherein the pH of the composition is from about 2.0 to about 5.0, preferably from about 2.1 to about 4.0, more preferably from about 2.5 to about 3.5, still more preferably from about 2.9 to about 3.1.

11. The composition according to any one of claims 1 to 10, wherein the buffer concentration is about 0.005 – 1 M, preferably 0.03 – 0.2 M, more preferably about 0.1 M.

12. The composition according to any one of claims 1-11 for use in the treatment or prevention of anxiety or agitation, and for use as a sedative or analgesic agent, and other diseases where alpha2A agonism is desired.

13. The composition according to any one of claims 1-11 for use in the treatment or

prevention of anxiety or agitation in humans.

14. Use of a composition comprising tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient in the manufacture of a medicament for the treatment or prevention of anxiety or agitation in humans.

15. Use according to claim 14, wherein the composition is as claimed in any one of claims 1-11.

16. Use according to claim 14 or 15, wherein the anxiety or agitation is associated with dementia.

17. A medicinal kit comprising a) a liquid pharmaceutical composition adapted for oral administration comprising tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient, b) a package for containing said composition, and c) instructions for administering said composition to a mammal, particularly human, for the treatment or prevention of anxiety or agitation.